Roivant Sciences (FRA:87S) ROIC %: -120.66% (As of Mar. 2026)


FRA:87S Roivant Sciences Ltd FRA:87S
55 GF Score
Price €30.01
GF Value €9.22
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences ROIC %?

Roivant Sciences FRA:87S +6.91% 55 ROIC % is -120.66% as of Mar. 2026. GuruFocus rates FRA:87S with a GF Score™ of 55/100 and a GF Value™ of €9.22 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Roivant Sciences's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -120.66%.

As of today (2026-06-26), Roivant Sciences's WACC % is 9.88%. Roivant Sciences's ROIC % is -189.11% (calculated using TTM income statement data). Roivant Sciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Roivant Sciences  (FRA:87S) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Roivant Sciences's WACC % is 9.88%. Roivant Sciences's ROIC % is -189.11% (calculated using TTM income statement data). Roivant Sciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Roivant Sciences ROIC % Related Terms


Roivant Sciences ROIC % Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences ROIC % Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROIC %
Get a 7-Day Free Trial -236.44 -132.51 -116.80 -191.63 -145.13

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -211.80 -229.69 -232.70 -225.44 -120.66

FRA:87S vs INSM, INCY, BNTX: ROIC % Comparison

For the Biotechnology subindustry, Roivant Sciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's ROIC % falls into.


FRA:87S
55GF Score
Roivant Sciences Ltd FRA:87S
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences ROIC % Calculation

Roivant Sciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Mar. 2026 is calculated as:

ROIC % (A: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2025 ) + Invested Capital (A: Mar. 2026 ))/ count )
=-1111.787 * ( 1 - 0% )/( (464.177 + 1067.985)/ 2 )
=-1111.787/766.081
=-145.13 %

where

Invested Capital(A: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5029.169 - 78.138 - ( 4520.374 - max(0, 138.205 - 4625.059+4520.374))
=464.177

Invested Capital(A: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4938.014 - 157.593 - ( 3712.436 - max(0, 243.276 - 4469.787+3712.436))
=1067.985

Roivant Sciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-1228.284 * ( 1 - 21.66% )/( (527.005 + 1067.985)/ 2 )
=-962.2376856/797.495
=-120.66 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4462.464 - 85.69 - ( 3868.601 - max(0, 129.777 - 3979.546+3868.601))
=527.005

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4938.014 - 157.593 - ( 3712.436 - max(0, 243.276 - 4469.787+3712.436))
=1067.985

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -120.66% mean?
Roivant Sciences (FRA:87S) has a ROIC % of -120.66% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Roivant Sciences and its competitors.
Is Roivant Sciences' ROIC % too high?
Roivant Sciences' current ROIC % is -120.66%. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' ROIC % compare to INSM and INCY?
Roivant Sciences' ROIC % of -120.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current ROIC % is -120.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (FRA:87S) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.22, compared to a current price of €30.01 — trading 225.5% above its estimated fair value. The current ROIC % is -120.66%. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Roivant Sciences (FRA:87S), the current ROIC % is -120.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (FRA:87S) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of €30.01 is trading 225.5% above its estimated GF Value™ of €9.22. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for FRA:87S:

  • ROIC %: -120.66%
  • GF Value™: €9.22 vs. price of €30.01 (225.5% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for FRA:87S

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.01
Price
€9.22
GF Value